rituximab
not tagged
 presents ielsg37. randomisation of pet d1-3 post 1l immunochemo pmbcl 545 pts but more pet+ than predicted trial has 86% power to show non-inf of omission of rt at 6% margin 30mo pfs &gt; 95% both arms! practice informing study. great work. #17icml 
Associate Professor of Haematology and lymphoma specialist at Oxford Cancer and Haematology centre. Christian, husband and father.